10x Genomics, Inc. (TXG) stock
TXGNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/30106% above fair value
$56.30+1.31 (+2.38%)
Close on Nov 17, 2026Market cap $7.34BP/E –Yield –
10x Genomics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
10x Genomics's total debt was $0 at Dec 31, 2020. For fiscal 2020 it was $0, down 100.0% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $0 | -100.0% |
| FY2019 | Dec 31, 2019 | $29.72M | +0.1% |
| FY2018 | Dec 31, 2018 | $29.68M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2020 | Dec 31, 2020 | $0 | -100.0% |
| Q3 FY2020 | Sep 30, 2020 | $0 | -100.0% |
| Q2 FY2020 | Jun 30, 2020 | $0 | -100.0% |
| Q1 FY2020 | Mar 31, 2020 | $0 | – |
| Q4 FY2019 | Dec 31, 2019 | $29.72M | – |
| Q3 FY2019 | Sep 30, 2019 | $29.69M | – |
| Q4 FY2018 | Dec 31, 2018 | $29.68M | – |
See a number that looks wrong?